Biotalys NV (BTLS.BR) • EURONEXT
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold BTLS.BR in your mock portfolio yet.
Biotalys NV is currently loss-making, as reflected in its negative EPS and PE ratio. The lack of positive earnings suggests the business is still in an investment or development phase, with profitability not yet in sight. This elevates execution and funding risk for equity holders.
The stock trades at €2.98, below its 200-day moving average of €3.27, signaling a prevailing downward or weak trend. A 4.5% decline over the last month reinforces near-term selling pressure and a lack of strong buying interest. Overall, technicals point to a cautious, downside-skewed setup.
Alternative data for Biotalys NV is modest and relatively static, offering limited evidence of accelerating commercial traction. Web traffic is low, hiring is flat at zero openings, and social media growth is minimal, though LinkedIn followers are reasonably high for a niche company. These signals neither strongly confirm nor contradict the bearish financial and technical picture.
Biotalys NV’s negative earnings profile, weak price action below its 200-day moving average, and modest alternative data signals collectively skew the outlook bearish. The stock appears to be a speculative bet on future developments rather than a fundamentally or technically strong name today. Until there is clearer progress toward profitability or stronger growth indicators, risk appears elevated relative to visible upside.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get Started